跳到正文
原文
JNNP 神经病学· Carvajal, R., Marcialis, C., Tur, C., Otero-Romero, S., Roos, I., Pappolla, A., Novak, F., Cobo-Calvo, A., Arino, H., Arrambide, G., Bollo, L., Casallas-Vanegas, A., Castillo, J., Comabella, M., Driemeyer, C., Elosua, I., Fadrique, C., Galan, I., Gravalos, M., La Puma, D., Masot, A., Midaglia, L., Molina-Goicoechea, M., Mongay-Ochoa, N., Rodriguez-Acevedo, B., Rio, J., Tagliani, P., Vidal-Jordana, A., Vilaseca-Jolonch, A., Zabalza, A., Pugliatti, M., Sastre-Garriga, J., Kalincik, T., Montalban, X., Tintore, M.·· 2026-10-13AI 评分48

多发性硬化症老年患者疾病修饰疗法停用后炎症风险分层依据

Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS

AI 导读

老年MS患者DMTs停用后炎症风险与年龄(>60岁)及治疗机制(抗CD20药物)显著相关。研究采用倾向得分匹配的前瞻队列设计,发现60岁以上患者炎症风险较年轻组降低,且抗CD20疗法停用后风险下降幅度最大。该结果为临床制定个体化停药方案提供了分层依据。

来源:JNNP 神经病学 · jnnp.bmj.com